secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2024-03-29T23:59:59+00:00
Accession:  0001493152-24-011834
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivos Therapeutics Reports FY2023 Revenue Decline, 27% OpEx Reduction, and FDA Clearance for Severe OSA
--------------------------------------------------------------------------------

- Revenue for Q4 2023 was $3.2M and full year $13.8M, down from $4.0M and $16.0M in 2022, due to lower appliance revenue and VIP enrollments.
- Operating expenses decreased 27% in FY2023, leading to a 43% reduction in net loss, as cost-cutting initiatives took effect.
- In November 2023, Vivos received FDA 510(k) clearance for its CARE oral appliances to treat severe OSA in adults, a first for oral devices.
- Signed VIP enrollment contracts increased 38% sequentially in Q4 2023 following the FDA clearance, indicating improved business momentum.
- Cash and equivalents were $1.6M at year-end; a warrant exercise in February 2024 generated $4.0M in gross proceeds.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315224011834/0001493152-24-011834-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315224011834/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-011834

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer